Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Case Report
87 (
1
); 49-53
doi:
10.4103/ijdvl.IJDVL_588_18
pmid:
31368453

Glucagonoma syndrome with atypical necrolytic migratory erythema

Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
Department of Dermatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
Corresponding author: Dr. Jinjing Jia, No. 111, Dade Road, Yuexiu District, Guangzhou 510120, Guangdong Province, China. 13310980167@163.com
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: He S, Zeng W, Geng S, Jia J. Glucagonoma syndrome with atypical necrolytic migratory erythema. Indian J Dermatol Venereol Leprol 2021;87:49-53.

Abstract

Necrolytic migratory erythema is most commonly associated with glucagonoma syndrome. We report a rare case of glucagonoma syndrome with necrolytic migratory erythema presenting as pruritic papules and follicular pustules in a 57-year-old woman; showing eosinophilic infiltration on histology. However, the final diagnosis was confirmed by demonstrating neuroendocrine tumour on histopathological examination of the liver metastases. Nutrition therapy was administered as a palliative treatment. This case also highlights the atypical clinical features and nonspecific histology of necrolytic migratory erythema which makes the diagnosis difficult.

Keywords

Glucagonoma syndrome
necrolytic migratory erythema
nutrition therapy

Introduction

Glucagonoma syndrome is a rare disease with an estimated incidence of 1 in 20 million. It is an alpha-cell-secreting tumor of the pancreas, accompanied by multiple clinical features including a characteristic rash termed as necrolytic migratory erythema, weight loss and mild diabetes mellitus in most patients, whereas normochromic normocytic anemia, painful glossitis, cheilitis and angular stomatitis have also been reported.1-3 Necrolytic migratory erythema is the presenting sign in almost 82% of the affected patients.2

Case Report

A 57-year-old woman was admitted to our ward with persistent skin lesions for the last 16 days. She also complained of anorexia, fatigue, intermittent diarrhea and a 10-kg weight loss for last 1 year. Drug history was positive for oral mosapride citrate tablets and compound digestive enzymes. Scattered itchy papules and follicular pustules developed on an erythematous base following the intake of mosapride and digestive enzymes. Initially they appeared around her ears which rapidly spread to her neck, trunk and limbs. Subsequently, these lesions developed active annular erythematous borders and central crusting. Perioral desquamation, glossitis and angular stomatitis were also observed [Figure 1]. Her general examination was unremarkable except for hyperglycemia and type 2 diabetes mellitus. Biopsy of the skin lesions revealed showed perivascular moderate eosinophil infiltration in the edematous papillary dermis [Figure 2]. Based on clinicopathogical correlation, we diagnosed drug eruption and administered intravenous hydroprednisone, compound glycyrrhizin, 18 essential amino acids and some essential fatty acids. However, there was scarce clinical improvement and most of the original lesions developed scaling, crusting, slight residual hyperpigmentation.

Figure 1a:: Erythematous scaly papules and pustules in the legs
Figure 1b:: Erythematous scaly papules and pustules in the neck
Figure 1c:: Erythematous scaly papules and pustules in the periauricular region
Figure 2:: Moderate eosinophil infiltration (yellow arrows) around the vessels in the edematous papillary dermis (H and E, ×400, bar length = 100 μm)

Routine blood biochemistry and bone marrow aspiration showed normochromic normocytic anemia (hemoglobin 74 g/L, red blood cells 2.4 × 1012/L, hematocrit 27.7%). The glycosylated hemoglobin level increased to 6.2%, and the albumin level decreased to 28.5 g/L (normal range 35–45 g/L). Enhanced abdominal computed tomography scanning revealed a 2 × 2 cm2 irregular mass on the tail of the pancreas along with multiple intrahepatic masses [Figure 3]. Further endocrinal investigations revealed a high level of glucagon at 3155.7 pg/mL (normal level ≤200 pg/mL); suggesting a diagnosis of glucagonoma with hepatic metastases. Repeat skin biopsy showed parakeratosis, intracellular edema and vacuolization in the upper spinous layer [Figure 4]. The histologic findings, along with the hormone levels, pancreatic neuroendocrine tumor and clinical presentation were together suggestive of glucagonoma syndrome with necrolytic migratory erythema. The presence of multiple metastases in the liver was a contraindication to surgery, and the patient refused chemotherapy because of concerns about adverse effects. After administration of octreotide and supplementation of amino acids, zinc and essential fatty acids, her lesions subsided with residual pigmentation [Figure 5].

Figure 3:: Enhanced abdominal computed tomography scan showing a mass in the tail of the pancreas (red arrow) and intrahepatic masses (yellow arrow)
Figure 4a:: Magnification in black box in the upper spinous layer (H and E, ×100, bar length = 100 μm)
Figure 4b:: Epidermal parakeratosis and vacuolated keratinocytes (red arrows) in the upper spinous layer (H and E, ×400, bar length = 100 μm)
Figure 5a:: Obvious improvement of skin lesions on the legs
Figure 5b:: Obvious improvement of skin lesions on the neck after treatment

Discussion

Early recognition of necrolytic migratory erythema is important because it can be the first and only manifestation of glucagonoma syndrome. The typical lesions of necrolytic migratory erythema initially appear as pruritic, irregular erythematous lesions with subsequent necrosis and crusting of the central part, leading to bullae, which progress to ulceration, crusting and scaling, and finally healing with hyperpigmentation.2,4-6 There are also some atypical presentations. Tremblay and Marcil had reported a case of necrolytic migratory erythema with vesicles and pustules in 2017.6 Toberer et al. also observed secondary pustules after erythema formation in a 38-year-old woman.7 The whole process evolves over a period of 2 weeks.1,5 Skin biopsy shows necrolysis of the upper spinous layer with confluent parakeratosis, pallor zone, vacuolated keratinocytes and keratinocyte degeneration. Lymphohistiocytic and neutrocytic infiltration can be found around the dilated vessels in the edematous papillary dermis.1,4,8

However, accurate diagnosis can be difficult, and necrolytic migratory erythema can sometimes be mistaken for other erythematous dermatoses. Urticarial vasculitis usually appears as an annular erythema similar to necrolytic migratory erythema. Eosinophilic cellulitis with edematous erythema, and eczema accompanied by erosions (pemphigus) also need to be differentiated. Skin biopsy and some extracutaneous observations can help confirm the diagnosis. Necrolytic acral erythema, which is closely associated with hepatitis C infection, bears microscopic and clinical resemblance to necrolytic migratory erythema.9 Drug eruption, which is usually characterized by the morphological diversity of the rash, may also cause diagnostic confusion. In our case, the patient had many classical extracutaneous features of glucagonoma syndrome. However, most of her lesions were itchy papules and follicular pustules, while typical erythematous vesicles and bullae were not observed. In addition, there was moderate eosinophilic infiltration of eosinophils in her histopathology, which has been barely reported previously. Though drug eruption was our primary diagnosis, mosapride and digestive enzymes are rarely the offending agents. The possibility of necrolytic migratory erythema was considered only after detecting a suspicious mass in the tail of pancreas. In retrospect, the clinical appearance of apparent erythematous base with active annular borders and central healing may help us identify necrolytic migratory erythema at the early stage. The second skin biopsy and other laboratory examinations finally confirmed the diagnosis of glucagonoma syndrome. Usually, by the time a diagnosis is made, at least 50% of patients already develop hepatic metastases. A curative surgical treatment is often impossible,3,6 as in our case. She also refused chemotherapy and other therapies, being apprehensive about their severe adverse effects. According to the pathogenesis of necrolytic migratory erythema, increased hepatocyte gluconeogenesis and lipolysis lead to hypoaminoacidemia resulting in epidermal protein deficiency and necrolysis. Additionally, nutritional or metabolic deficiency of zinc or essential fatty acids may play an important role. Therefore, somatostatin analogs, octreotide, amino acids and essential fatty acids are administered to relieve symptoms, and they also provide a good curative effect.1,2,10 Our case was also given similar treatment to result in symptomatic improvement. However, even if the pancreatic tumor is not removed, the course of glucagonoma syndrome can routinely exhibit spontaneous remission with reappearance of the skin lesions in the later stage; thus close follow-up such patients is needed.

Interestingly, all patients with glucagonoma syndrome do not present with typical migratory erythema. Early-stage or atypical necrolytic migratory erythema can manifest as erythematous, erosive, crusted plaques, which can be misdiagnosed as psoriasis vulgaris. Skin biopsy shows psoriasiform dermatitis with compact parakeratosis and morphologically consistent subcorneal pustules.11 Pustules and vasculitis-like lesions are being reported lately.

To conclude, necrolytic migratory erythema can appear in diverse forms on the base of erythema with annular borders. Dermatologists should be able to identify the main morphological characteristics of lesions, and in the presence of suspicious systemic symptoms, possible cutaneous manifestations of glucagonoma tumor should be considered.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

This study was supported by the National Natural Science Foundation of China (81803136), Guangzhou Traditional Chinese Medicine Science and Technology Innovation Platform Construction Project (Guangdong Traditional Chinese Medicine Letter[2017] 340) and the Second Affiliated Hospital of Xi’an Jiaotong University.

Conflicts of interest

There are no conflicts of interest.

References

  1. , . Glucagonoma syndrome: A review and update on treatment. J Eur Acad Dermatol Venereol. 2016;30:2016-22.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , . Glucagonoma syndrome. In: , , , , , , eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; .
    [Google Scholar]
  3. , , , , , . The glucagonoma syndrome and necrolytic migratory erythema: A clinical review. Eur J Endocrinol. 2004;151:531-7.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , . Normoglycemic glucagonoma syndrome associated with necrolytic migratory erythema. J Eur Acad Dermatol Venereol. 2018;32(8):e306-e307.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , . A review of cutaneous manifestations within glucagonoma syndrome: Necrolytic migratory erythema. Int J Dermatol. 2018;57:642-5.
    [CrossRef] [PubMed] [Google Scholar]
  6. , . Necrolytic migratory erythema: A forgotten paraneoplastic condition. J Cutan Med Surg. 2017;21:559-61.
    [CrossRef] [PubMed] [Google Scholar]
  7. , , . Glucagonoma-associated necrolytic migratory erythema: The broad spectrum of the clinical and histopathological findings and clues to the diagnosis. Am J Dermatopathol. 2019;41:e29-32.
    [CrossRef] [PubMed] [Google Scholar]
  8. , , , , , , et al. Delayed diagnosis of glucagonoma syndrome: A case report. Int J Dermatol. 2016;55:1272-4.
    [CrossRef] [PubMed] [Google Scholar]
  9. , , . Necrolytic acral erythema: A review of the literature. Cutis. 2009;83:309-14.
    [Google Scholar]
  10. , , , . Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clin Endocrinol (Oxf). 2002;57:827-31.
    [CrossRef] [PubMed] [Google Scholar]
  11. , , , , . Psoriasiform lesions: Uncommon presentation of glucagonoma. Gastroenterol Hepatol. 2018;41:500-2.
    [CrossRef] [Google Scholar]

Fulltext Views
1,496

PDF downloads
725
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections